Neurological Manifestations Associated with Synthetic Cannabinoid Use- A Case Series
Marwa Elnazeir1, *0000-0003-2697-0980, Siddharth Narayanan2, *0000-0002-5553-3221, Pradeepthi Badugu30000-0002-6396-8030, Abid Hussain20000-0002-6172-9407, Cody B Stephens20000-0001-7730-3665, Riwaj Bhagat10000-0002-8783-4440, Christopher M Jones2, Wei Liu10000-0001-6912-2194, Alexi R Hernandez1, Kerri S Remmel1, Adriana E Palade1, *0000-0002-4828-8459
Synthetic Cannabinoid (SC) use has emerged as a growing public health threat in the United States. Several unexpected cases, presenting with a constellation of unrelated symptoms, but all having toxicity linked to SC use, have been reported in the last decade (2010-2019).
We report a cluster of several independent cases where patients were admitted having different neurological manifestations. Extensive and expensive work-ups were performed. Upon further inspection, extended toxicology screens were found to be positive for SC metabolites.
It is alarming to observe that several reports highlight an increase in the varied and significant morbidity associated after SC use. Various SC compositions have been synthesized and distributed, with new molecules being generated at a staggering rate leading to unexpected manifestations.
Young people are the most frequent users owing to its recreational effects, its easy accessibility, lower cost and difficulty in being detected in the urine by routine drug screens. From a hospital quality improvement perspective, efforts to characterize the presence of newly generated SC molecules and establish more accessible in-house screening methods will be a starting step in reducing the associated cost-burden. This will also minimize the unnecessary invasive procedures performed on a specific patient. From a socioeconomic viewpoint, solid and systematic crosstalk with increased recognition and reporting mechanism between the healthcare staff and public health personnel is strongly warranted to support state and federal regulatory efforts in combating this ongoing SC epidemic.
* Address correspondence to this author at the Department of Neurology, University of Louisville, 500 South Preston Street, Louisville, KY, 40202, USA; Tel: +1.502.588.4800; E-mail: email@example.com